{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:55:25Z","timestamp":1781286925789,"version":"3.54.1"},"reference-count":33,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The porphyrias are a family of metabolic disorders caused by defects in the activity of one of the enzymes in the heme biosynthetic pathway. Acute intermittent porphyria (AIP), caused by autosomal dominant mutations in the gene encoding hydroxymethylbilane synthase, can lead to hepatocyte overaccumulation and systemic distribution of the proximal porphyrin precursors, 5-aminolevulinic acid (ALA) and porphobilinogen (PBG). ALA and PBG are toxic to neurons and extrahepatic tissue and cause the neurovisceral clinical manifestations of AIP. Management of AIP includes awareness and avoidance of triggering factors, infusions of hemin for severe acute attacks, and, if indicated for chronic suppressive therapy, maintenance treatment with hemin or givosiran, a small interfering RNA molecule that antagonizes ALA synthase 1 transcripts. Erythropoietic protoporphyria (EPP) is most commonly caused by autosomal recessive mutations in the gene encoding ferrochelatase (FECH), the heme pathway terminal enzyme. FECH deficiency leads to erythrocyte overaccumulation and high plasma levels of lipophilic protoporphyrins that photoactivate in the skin, causing burning pain and erythema. Protoporphyrins excreted in the bile can cause gallstones, cholestasis, fibrosis, and ultimately liver failure. Management of EPP includes skin protection and afamelanotide, an \u03b1-melanocyte stimulating hormone analog that increases melanin pigment and reduces photoactivation. Liver transplantation may be necessary for severe EPP-induced liver complications. Because AIP and EPP arise from defects in the heme biosynthetic pathway, hematologists are often consulted to evaluate and manage suspected or proven porphyrias. A working knowledge of these disorders increases our confidence and effectiveness as consultants and medical providers.<\/jats:p>","DOI":"10.1182\/hematology.2020000124","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T03:17:04Z","timestamp":1607138224000},"page":"400-410","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP"],"prefix":"10.1182","volume":"2020","author":[{"given":"Michael","family":"Linenberger","sequence":"first","affiliation":[{"name":"University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kleber Y.","family":"Fertrin","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2020121621162696600_B1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2019.04.050","article-title":"Clinical guide and update on porphyrias","volume":"157","author":"St\u00f6lzel","year":"2019","journal-title":"Gastroenterology"},{"issue":"9","key":"2020121621162696600_B2","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1056\/NEJMra1608634","article-title":"Porphyria","volume":"377","author":"Bissell","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2020121621162696600_B3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ymgme.2018.11.012","article-title":"Recent advances on porphyria genetics: inheritance, penetrance & molecular heterogeneity, including new modifying\/causative genes","volume":"128","author":"Yasuda","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"11","key":"2020121621162696600_B4","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1038\/s41436-019-0537-7","article-title":"International Porphyria Molecular Diagnostic Collaborative: an evidence-based database of verified pathogenic and benign variants for the porphyrias","volume":"21","author":"Chen","year":"2019","journal-title":"Genet Med"},{"issue":"12","key":"2020121621162696600_B5","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/gim.2018.38","article-title":"False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care","volume":"20","author":"Tandy-Connor","year":"2018","journal-title":"Genet Med"},{"issue":"4","key":"2020121621162696600_B6","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/hep.29313","article-title":"Acute hepatic porphyrias: recommendations for evaluation and long-term management","volume":"66","author":"Balwani","year":"2017","journal-title":"Hepatology"},{"issue":"3","key":"2020121621162696600_B7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2019.07.002","article-title":"Acute hepatic porphyrias: current diagnosis & management","volume":"128","author":"Anderson","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2020121621162696600_B8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2119\/molmed.2015.00099","article-title":"Liver transplantation for acute intermittent porphyria: biochemical and pathologic studies of the explanted liver","volume":"21","author":"Yasuda","year":"2015","journal-title":"Mol Med"},{"issue":"1","key":"2020121621162696600_B9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/joim.12750","article-title":"Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver","volume":"284","author":"Schmitt","year":"2018","journal-title":"J Intern Med"},{"issue":"11","key":"2020121621162696600_B10","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/hmg\/ddz003","article-title":"Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria","volume":"28","author":"Yasuda","year":"2019","journal-title":"Hum Mol Genet"},{"issue":"3","key":"2020121621162696600_B11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ymgme.2019.03.002","article-title":"Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs)","volume":"128","author":"Bonkovsky","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"2","key":"2020121621162696600_B12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/ckj\/sfx146","article-title":"Porphyria and kidney diseases","volume":"11","author":"Pallet","year":"2018","journal-title":"Clin Kidney J"},{"issue":"3","key":"2020121621162696600_B13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ymgme.2018.10.001","article-title":"Hepatocellular carcinoma in acute hepatic porphyrias: a Damocles Sword","volume":"128","author":"Peoc\u2019h","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"12","key":"2020121621162696600_B14","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.amjmed.2014.06.036","article-title":"Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium","volume":"127","author":"Bonkovsky","year":"2014","journal-title":"Am J Med"},{"issue":"5","key":"2020121621162696600_B15","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/hep.30936","article-title":"EXPLORE: a prospective, multinational, natural history study of patients with acute hepatic porphyria with recurrent attacks","volume":"71","author":"Gouya","year":"2020","journal-title":"Hepatology"},{"issue":"5","key":"2020121621162696600_B16","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s10545-018-0178-z","article-title":"Medical and financial burden of acute intermittent porphyria [published correction appears in J Inherit Metab Dis. 2018;41(6):1297-1298]","volume":"41","author":"Neeleman","year":"2018","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"2020121621162696600_B17","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41436-019-0683-y","article-title":"Evaluating the Patient-Reported Outcomes Measurement Information System scales in acute intermittent porphyria","volume":"22","author":"Naik","year":"2020","journal-title":"Genet Med"},{"issue":"24","key":"2020121621162696600_B18","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"2020121621162696600_B19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1172-4-19","article-title":"Erythropoietic protoporphyria","volume":"4","author":"Lecha","year":"2009","journal-title":"Orphanet J Rare Dis"},{"key":"2020121621162696600_B20","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jpeds.2018.06.001","article-title":"Diagnostic delay in erythropoietic protoporphyria","volume":"202","author":"Lala","year":"2018","journal-title":"J Pediatr"},{"issue":"8","key":"2020121621162696600_B21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamadermatol.2017.1557","article-title":"Clinical, biochemical, and genetic characterization of North American patients with erythropoietic protoporphyria and X-linked protoporphyria","volume":"153","author":"Balwani","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"1","key":"2020121621162696600_B22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bcmd.2014.07.017","article-title":"In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentration correlates with iron availability","volume":"54","author":"Barman-Aks\u00f6zen","year":"2015","journal-title":"Blood Cells Mol Dis"},{"issue":"12","key":"2020121621162696600_B23","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1373\/clinchem.2015.245456","article-title":"Pitfalls in erythrocyte protoporphyrin measurement for diagnosis and monitoring of protoporphyrias","volume":"61","author":"Gou","year":"2015","journal-title":"Clin Chem"},{"issue":"38","key":"2020121621162696600_B24","doi-asserted-by":"crossref","first-page":"E8045","DOI":"10.1073\/pnas.1700632114","article-title":"Mutation in human CLPX elevates levels of \u03b4-aminolevulinate synthase and protoporphyrin IX to promote erythropoietic protoporphyria","volume":"114","author":"Yien","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2020121621162696600_B25","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/lt.21527","article-title":"Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria","volume":"14","author":"Wahlin","year":"2008","journal-title":"Liver Transpl"},{"issue":"3","key":"2020121621162696600_B26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ymgme.2019.01.020","article-title":"Erythropoietic protoporphyria and X-linked protoporphyria: pathophysiology, genetics, clinical manifestations, and management","volume":"128","author":"Balwani","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"3","key":"2020121621162696600_B27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ymgme.2019.07.017","article-title":"Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria","volume":"128","author":"Parker","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2020121621162696600_B28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMoa1411481","article-title":"Afamelanotide for erythropoietic protoporphyria","volume":"373","author":"Langendonk","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"2020121621162696600_B29","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/bjd.15893","article-title":"Osteoporosis in patients with erythropoietic protoporphyria","volume":"177","author":"Biewenga","year":"2017","journal-title":"Br J Dermatol"},{"issue":"6","key":"2020121621162696600_B30","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jca.21249","article-title":"Plasma and red cell exchange transfusions for erythropoietic protoporphyria: a case report and review of the literature","volume":"27","author":"Pagano","year":"2012","journal-title":"J Clin Apher"},{"issue":"3","key":"2020121621162696600_B31","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.27086","article-title":"Liver transplantation in the management of porphyria","volume":"60","author":"Singal","year":"2014","journal-title":"Hepatology"},{"issue":"2","key":"2020121621162696600_B32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/bmt.2009.132","article-title":"The role for BMT in erythropoietic protoporphyria","volume":"45","author":"Wahlin","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2020121621162696600_B33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ajhg.2018.12.021","article-title":"Erythroid-progenitor-targeted gene therapy using bifunctional TFR1 ligand-peptides in human erythropoietic protoporphyria","volume":"104","author":"Mirmiran","year":"2019","journal-title":"Am J Hum Genet"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/400\/1794761\/hem2020000124c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/400\/1794761\/hem2020000124c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T18:11:05Z","timestamp":1608315065000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/400\/474288\/Updates-on-the-diagnosis-and-management-of-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000124","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}